PTAB deals Bass another blow
Bass suffers another IPR setback
Nejron Photo / Shutterstock.com
Hedge fund manger Kyle Bass has secured his first inter partes review (IPR) trial after the Patent Trial and Appeal Board (PTAB) instituted a challenge against a patent owned by biopharmaceutical company Shire.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Kyle Bass; PTAB; USPTO; Coalition for Affordable Drugs; Lialda; IPR; Shire; Cosmo Technologies